| Literature DB >> 32446972 |
Marie Fidela R Paraiso1, Jubilee Brown2, Mauricio S Abrão3, Humberto Dionisi4, Richard B Rosenfield5, Ted T M Lee6, Nucelio Lemos7.
Abstract
Entities:
Mesh:
Year: 2020 PMID: 32446972 PMCID: PMC7242200 DOI: 10.1016/j.jmig.2020.05.012
Source DB: PubMed Journal: J Minim Invasive Gynecol ISSN: 1553-4650 Impact factor: 4.137
Suggested prioritization criteria (Adapted from Prachand et al, 2020)
| Allocated Prioritization Score | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| Procedure factors | |||||
| Score | 1 | 2 | 3 | 4 | 5 |
| OR time (min) | <30 | 31–30 | 61–120 | 121–180 | ≥180 |
| Estimated LOS | Outpatient | <24h | 24–48h | 2–3d | ≥4d |
| Risk of postoperative ICU | Very unlikely | <5% | 5%–10% | >10%–25% | >25% |
| Anticipated blood loss (mL) | <100 | 100–250 | 250–500 | 500–750 | >750 |
| Surgical team size (n) | 1 | 2 | 3 | 4 | >4 |
| Intubation probability (%) | <1 | 1–5 | 6–10 | 11–25 | >25 |
| Surgical site/access | None of the following | Abdominopelvic MIS | Abdominopelvic open surgery, infraumbilical | Abdominopelvic open surgery, supraumbilical | OHNS/upper GI/thoracic |
| Disease factors | |||||
| Nonoperative option effectiveness | None available | Available, <40% as effective as surgery | Available, 40%–60% as effective as surgery | Available, 61%–95% as effective as surgery. | Available, 96% to ass effective as surgery |
| Nonoperative treatment option resource/ exposure risk | Significantly worse/not applicable | Somewhat worse | Equivalent | Somewhat better | Significantly better |
| Impact of 2-wk delay in treatment outcome | Significantly worse | Worse | Moderately worse | Slightly worse | No worse |
| Impact of 2-wk delay in surgical difficulty/risk | Significantly worse | Worse | Moderately worse | Slightly worse | No worse |
| Impact of 6-wk delay in treatment outcome | Significantly worse | Worse | Moderately worse | Slightly worse | No worse |
| Impact of 6-wk delay in surgical difficulty/risk | Significantly worse | Worse | Moderately worse | Slightly worse | No worse |
| Patient factors | |||||
| Age (yrs) | ≤20 | 21–40 | 41–50 | 51–65 | >65 |
| Lung disease (asthma, COPD, CF) | None | – | – | Minimal (rare inhaler) | >Minimal |
| Obstructive sleep apnea | Not present | – | – | Mild/Moderate (no CPAP) | On CPAP |
| CV Disease (HTN, CHF, CAD) | None | Minimal (no meds) | Mild (1 med) | Moderate (2 meds) | Severe (≥3 meds) |
| Diabetes | None | – | Mild (no meds) | Moderate (PO meds only) | > Moderate (insulin) |
| Immunocompromised | No | – | – | Moderate | Severe |
| ILI symptoms (fever, cough, sore throat, body aches, diarrhea) | None (Asymptomatic) | – | – | – | Yes |
| Exposure to known COVID-19 positive person in past 14 days | No | Probably not | Possibly | Probably | Yes |
CAD = coronary artery disease; CF = cystic fibrosis; CHF = congestive heart failure; COPD = Chronic obstructive pulmonary disease; COVID-19 = coronavirus disease; CPAP = continuous positive airway pressure; CV = cardiovascular; GI = gastrointestinal; HTN = hypertension; ICU = intensive care unit; ILI = influenza-like illness; LOS = length of stay; med = medication; MIS = minimally invasive surgery; OHNS = otolaryngology, head & neck surgery; OR = operating room PO = by mouth.
Hematologic malignancy, stem cell transplant, solid organ transplant, active/recent cytotoxic chemotherapy, anti-TNFα or other immunosuppressants, >20 mg prednisone equivalent/day, congenital immunodeficiency, hypogammaglobulinemia on intravenous immunoglobulin, AIDS.
Fig. 1COVID-19 Preoperative Surgery Decision Tree. COVID-19 = coronavirus disease; Neg = negative; Pos = positive; post-op = postoperative. Courtesy of Cleveland Clinic Reactivation Task Force [14].